Scarica l'app Stockscreener
10.80
2.44%
-0.27
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Update Recap: How does Entrada Therapeutics Inc compare to its peersGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Can Entrada Therapeutics Inc maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Technical Reactions to TRDA Trends in Macro Strategies - Stock Traders Daily
Entrada Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Entrada CEO Dipal Doshi to join biotech investor talks in New York, Boston - stocktitan.net
Aug Opening: Is STERIS plc stock a good pick for beginnersDollar Strength & Verified High Yield Trade Plans - baoquankhu1.vn
Stock Report: What are the risks of holding Entrada Therapeutics IncQuarterly Performance Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Aug Shorts: Is Entrada Therapeutics Inc benefiting from innovation trendsRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Update Recap: Can Entrada Therapeutics Inc outperform under higher oil prices - baoquankhu1.vn
US Market Recap: How volatile is MOGB stockEarnings Summary Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Trading the Move, Not the Narrative: (TRDA) Edition - Stock Traders Daily
What insider trading reveals about Entrada Therapeutics Inc. stock2025 Momentum Check & AI Forecasted Stock Moves - bollywoodhelpline.com
Will Entrada Therapeutics Inc outperform the market in YEARTrade Volume Report & Fast Gain Stock Tips - baoquankhu1.vn
Signal Recap: Is Eastman Chemical Company stock a buy or sell2025 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
Quarterly Earnings: Can Onconetix Inc weather a recession2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
(TRDA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Smart Money: Is Entrada Therapeutics Inc part of any major index2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 4.8%Should You Sell? - MarketBeat
Entrada updates progress in preclinical pipeline - BioWorld MedTech
Entrada Therapeutics reports progress across development portfolio - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Analyst Calls: Is Entrada Therapeutics Inc. stock safe for conservative investorsQuarterly Investment Review & AI Driven Stock Reports - Улправда
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risks2025 Market Trends & Accurate Technical Buy Alerts - Улправда
Entrada Therapeutics Highlights Progress Across Its Portfolio of Rna-Based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - marketscreener.com
Entrada Therapeutics highlights RNA pipeline progress and outlook - TipRanks
Entrada reports progress on DMD treatments, shares clinical timeline By Investing.com - Investing.com Australia
Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection - Quiver Quantitative
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - The Manila Times
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewswire Inc.
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Azenta elects Entrada CEO to Board of Directors - MSN
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - Bộ Nội Vụ
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics Earnings Notes - Trefis
How Entrada Therapeutics Inc. stock compares to industry benchmarksDay Trade & Safe Capital Allocation Plans - Улправда
Is Entrada Therapeutics Inc. stock positioned for long term growth2025 Volume Leaders & Fast Momentum Stock Entry Tips - Улправда
Is Entrada Therapeutics Inc. stock safe for conservative investors2025 Big Picture & Verified Trade Idea Suggestions - Улправда
How Entrada Therapeutics Inc. stock reacts to job market dataWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
How resilient is Entrada Therapeutics Inc. stock in market downturnsJuly 2025 Snapshot & Weekly High Return Stock Forecasts - DonanımHaber
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Will Entrada Therapeutics Inc. stock benefit from commodity pricesWeekly Trading Summary & Verified Technical Signals - DonanımHaber
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: A 47% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Entrada Therapeutics : Corporate Presentation December 2025 - marketscreener.com
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA - MarketBeat
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):